Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00590863 · ClinicalTrials.gov registry record · Phase 4
Combining Medications to Enhance Depression Outcomes
A Phase 4 study of Major Depressive Disorder, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- Phase 4
- Development phase
- 665
- Enrollment target
- 15
- Study locations
NCT00590863: Completed Phase 4 study of Major Depressive Disorder, sponsored by National Institute of Mental Health (NIMH).
NCT00590863 is a Phase 4 study of Major Depressive Disorder that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 665 participants, above the 374-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (78% higher). The trial reports 15 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00590863, a Phase 4 study of Major Depressive Disorder, has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 665 participants
- Enrollment target
- 15
- Study locations
Study Summary
This study will compare whether a combination of antidepressant medications is better than one antidepressant medication alone when given as initial treatment for people with chronic or recurrent major depressive disorder.
Primary Outcome
Percentage of patients that achieve remission, as defined as QIDS total score below 6 for last 2 study visits. QIDS depression scores range from 0 (normal) to 27 (very severe).
Conditions Studied
Interventions
- DRUG SSRI + placebo
- DRUG Escitalopram + Bupropion SR
- DRUG Venlafaxine XR + Mirtazapine
Study Locations (15)
California
- Harbor UCLA Family Health Care Center - Harbor City
- UCLA Internal Medicine Clinic - Los Angeles
- Veterans Affairs Medical Center/FIRM Primary Care Clinic - San Diego
Alabama
- Tuscalossa VA Mental Health Clinic - Tuscaloosa
Illinois
- Northwestern Psychiatric Outpatient Treatment Care Center - Chicago
Kansas
- Clinical Research Institute - Wichita
Massachusetts
- MGH/Northshore Medical Center (Salem Psychiatric Facility) - Salem
Michigan
- General Psychiatric Ambulatory Clinic - Ann Arbor
New York
- Irving Goldman Primary Care at North Shore Hospital - New York
North Carolina
- UNC Chapel Hill Adult Diagnostic & Treatment Clinic - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 665 participants |
| Start Date | 2008-03 |
| Est. Completion | 2009-09 |
| Phase | Phase 4 |
What the finished NCT00590863 record still lists
NCT00590863 is an interventional study that assigns participants to a tested intervention. The registered 665 participants enrollment target is mid-sized for trials with a published cap, above the 374-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (78% higher).
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 3 interventions - of which SSRI + placebo is the first listed.
NCT00590863 lists 15 locations in 13 states (California, Alabama, Illinois).
Frequently Asked Questions
What is clinical trial NCT00590863 about?
NCT00590863 is a clinical study titled "Combining Medications to Enhance Depression Outcomes". This study will compare whether a combination of antidepressant medications is better than one antidepressant medication alone when given as initial treatment for people with chronic or recurrent major depressive disorder.
What is the current status of trial NCT00590863?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 665 participants. The study started on 2008-03. Estimated completion is 2009-09.
What conditions does trial NCT00590863 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT00590863?
The interventions under investigation include: SSRI + placebo (DRUG), Escitalopram + Bupropion SR (DRUG), Venlafaxine XR + Mirtazapine (DRUG).
Who is sponsoring clinical trial NCT00590863?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00590863 being conducted?
This trial has 15 study locations across Alabama, California, Illinois, Kansas, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00590863's enrollment target sits among peer trials
665 20th of 282 higher than 263 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
RECRUITING · Phase 4
-
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
RECRUITING · Phase 4
-
Neural Circuit Effects of Ketamine in Depression
RECRUITING · Phase 4
-
Aβ Dynamics in LLMD
RECRUITING · Phase 4
-
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04064060 · 665 participants · Phase 3
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
- NCT06328647 · 666 participants · NA
Quantra Point-of-Care Hemostasis Monitoring
- NCT06981078 · 666 participants · Phase 2
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
- NCT06607341 · 664 participants · NA
Community Engagement Alliance Against Disparities
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia